Our recent efforts to explore the sensitivity factors for cisplatin treatment in NPC cells have revealed that asparagine synthetase, matrix metalloproteinase 19, and eIF3a confer cisplatin sensitivity to NPC cells [9], [10]. This evidence concerns the gene EIF3A and nasopharyngeal carcinoma.